These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 12915048)

  • 21. Neuroprotective effect of nicotine on dopaminergic neurons by anti-inflammatory action.
    Park HJ; Lee PH; Ahn YW; Choi YJ; Lee G; Lee DY; Chung ES; Jin BK
    Eur J Neurosci; 2007 Jul; 26(1):79-89. PubMed ID: 17581257
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease.
    Collins LM; Toulouse A; Connor TJ; Nolan YM
    Neuropharmacology; 2012 Jun; 62(7):2154-68. PubMed ID: 22361232
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease.
    Kim S; Moon M; Park S
    J Endocrinol; 2009 Sep; 202(3):431-9. PubMed ID: 19570816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration.
    Morale MC; Serra PA; L'episcopo F; Tirolo C; Caniglia S; Testa N; Gennuso F; Giaquinta G; Rocchitta G; Desole MS; Miele E; Marchetti B
    Neuroscience; 2006; 138(3):869-78. PubMed ID: 16337092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rosiglitazone decreases peroxisome proliferator receptor-γ levels in microglia and inhibits TNF-α production: new evidences on neuroprotection in a progressive Parkinson's disease model.
    Carta AR; Frau L; Pisanu A; Wardas J; Spiga S; Carboni E
    Neuroscience; 2011 Oct; 194():250-61. PubMed ID: 21839812
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glial reactions in Parkinson's disease.
    McGeer PL; McGeer EG
    Mov Disord; 2008 Mar; 23(4):474-83. PubMed ID: 18044695
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The MitoPark Mouse - an animal model of Parkinson's disease with impaired respiratory chain function in dopamine neurons.
    Ekstrand MI; Galter D
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S185-8. PubMed ID: 20082987
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nicotine neuroprotection against nigrostriatal damage: importance of the animal model.
    Quik M; O'Neill M; Perez XA
    Trends Pharmacol Sci; 2007 May; 28(5):229-35. PubMed ID: 17412429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extract of Tripterygium wilfordii Hook F protect dopaminergic neurons against lipopolysaccharide-induced inflammatory damage.
    Liu Y; Chen HL; Yang G
    Am J Chin Med; 2010; 38(4):801-14. PubMed ID: 20626064
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase.
    Zhang W; Wang T; Qin L; Gao HM; Wilson B; Ali SF; Zhang W; Hong JS; Liu B
    FASEB J; 2004 Mar; 18(3):589-91. PubMed ID: 14734632
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Controversies on new animal models of Parkinson's disease pro and con: the rotenone model of Parkinson's disease (PD).
    Schmidt WJ; Alam M
    J Neural Transm Suppl; 2006; (70):273-6. PubMed ID: 17017541
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation.
    Delgado M; Ganea D
    FASEB J; 2003 May; 17(8):944-6. PubMed ID: 12626429
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuroinflammation and oxidative stress: co-conspirators in the pathology of Parkinson's disease.
    Taylor JM; Main BS; Crack PJ
    Neurochem Int; 2013 Apr; 62(5):803-19. PubMed ID: 23291248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Commentary: Progressive inflammation as a contributing factor to early development of Parkinson's disease.
    Pradhan S; Andreasson K
    Exp Neurol; 2013 Mar; 241():148-55. PubMed ID: 23261765
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inflammation in Parkinson's disease: causative or epiphenomenal?
    Hald A; Van Beek J; Lotharius J
    Subcell Biochem; 2007; 42():249-79. PubMed ID: 17612055
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protective effects of Chunghyuldan against ROS-mediated neuronal cell death in models of Parkinson's disease.
    Kim HG; Ju MS; Kim DH; Hong J; Cho SH; Cho KH; Park W; Lee EH; Kim SY; Oh MS
    Basic Clin Pharmacol Toxicol; 2010 Dec; 107(6):958-64. PubMed ID: 20629656
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modeling neuroinflammatory pathogenesis of Parkinson's disease.
    Barnum CJ; Tansey MG
    Prog Brain Res; 2010; 184():113-32. PubMed ID: 20887872
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel anti-inflammatory and neuroprotective agents for Parkinson's disease.
    Lu L; Li F; Wang X
    CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):232-40. PubMed ID: 20015029
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inflammation and neurodegeneration in Parkinson's disease.
    McGeer PL; McGeer EG
    Parkinsonism Relat Disord; 2004 May; 10 Suppl 1():S3-7. PubMed ID: 15109580
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Isothiocyanates Are Promising Compounds against Oxidative Stress, Neuroinflammation and Cell Death that May Benefit Neurodegeneration in Parkinson's Disease.
    Sita G; Hrelia P; Tarozzi A; Morroni F
    Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27598127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.